Camurus listed on Nasdaq Stockholm
The shares in Camurus AB (publ) have on 3 December 2015 been admitted to trading on Nasdaq Stockholm. The listing included an offer by the company and its principal shareholder, Sandberg Development AB, to the general public in Sweden and qualified institutional investors in Sweden and abroad to acquire existing and newly issued shares in the company corresponding to 30 per cent of the total number of shares. In addition, Sandberg Development has granted an over-allotment option of not more than 15 percent of the offering. Sandberg Development remains the principal shareholder in Camurus following the listing.
When the trading commenced, the company was valued to approx. SEK 2.1 billion with a final price in the offering of SEK 57 per share. The company raised a total of SEK 500 million in the offering.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies.
Camurus and the principal shareholder Sandberg Development were advised by Mannheimer Swartling in the offering and the listing. The firm’s team was led by Madeleine Rydberger and Hans Petersson, mainly assisted by Nils Nostell, Jakob Wijkander, Aleksander Ivarsson, Klara Holm and Jacob Rosell Svensson. Maria Tufvesson Shuck and Hampus Thofte from the firm’s New York office advised on U.S. securities law. Anders Erasmie advised on tax matters, mainly assisted by Carl Beyer.